<DOC>
	<DOC>NCT02467348</DOC>
	<brief_summary>All consecutive patients admitted in ILBS from MAY 2015 to DECEMBER 2016.ACLF (Acute on chronic Liver Failure). ACLF will be randomize into Group 1: MVP (Modest Volume Paracentesis) OF Less than 5 liters with IV albumin at a dose 8 gms/L of ascitic fluid Group 2: MVP (Modest Volume Paracentesis) of Less than 5 liters without albumin</brief_summary>
	<brief_title>Incidence And Outcome Of Paracentesis Induced Circulatory Dysfunction In Acute-On-Chronic Liver Failure.</brief_title>
	<detailed_description />
	<mesh_term>Liver Failure</mesh_term>
	<mesh_term>End Stage Liver Disease</mesh_term>
	<mesh_term>Acute-On-Chronic Liver Failure</mesh_term>
	<criteria>1. All patients with acute hepatic insult manifesting as jaundice (Sr. Bil. ≥ 5 mg/dL) and coagulopathy (INR≥1.5), complicated within 4 weeks by ascites and/or encephalopathy in a patient with previously diagnosed or undiagnosed chronic liver disease (ACLF) admitted in the hospital. 2. All Cirrhotics decompensated with ascites admitted in the hospital. 3. Grade II/III ascites 4. Need for paracentesis. 1. Age &lt;12 or &gt; 75 years 2. Hepatocellular carcinoma 3. Non cirrhotic ascites such as malignancy or tubercular peritonitis 4. Serum Cr &gt;1.5mg% 5. Refractory septic shock 6. Grade III/IV hepatic encephalopathy 7. Abdominal wall cellulitis 8. Active variceal bleed 9. Respiratory, cardiac and renal failure 10. Refusal to participate in the study</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>